ErVimmune

Lyon, France

ErVimmune develops cancer vaccines and T cell therapies targeting cold tumors using AI-driven antigen discovery.

$19.9M raised

Jan 2026

Series A

Top Investors

Seventure PartnersSPRIM Global Investments

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has ErVimmune raised?

ErVimmune has raised $19.9M in total funding. The most recent round was Series A. The last funding was announced in January 2026.

Who are ErVimmune's investors?

ErVimmune's investors include Seventure Partners, SPRIM Global Investments.

Where is ErVimmune headquartered?

ErVimmune is headquartered in Lyon, France.

What does ErVimmune do?

ErVimmune develops cancer vaccines and T cell therapies targeting cold tumors using AI-driven antigen discovery.

What stage is ErVimmune at?

ErVimmune is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 21, 2026.

MLA

"ErVimmune — Funding & Investors." VCBacked, January 21, 2026, https://www.vcbacked.co/company/ervimmune. Accessed June 3, 2026.

APA

VCBacked. (2026). ErVimmune — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/ervimmune

Wikipedia (cite web)

{{cite web |title=ErVimmune — Funding & Investors |url=https://www.vcbacked.co/company/ervimmune |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 21, 2026.